ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• ADAM9 (a disintegrin and metalloproteinase 9) is implicated in cancer cell adhesion and invasion.
• High ADAM9 expression is observed in various cancer types.

Purpose of the Study:

• To investigate the role of ADAM9 in lung cancer metastasis and angiogenesis in vivo.
• To explore ADAM9 as a prognostic marker and therapeutic target for lung cancer.

Main Methods:

• Correlation analysis of ADAM9 expression with lung adenocarcinoma patient prognosis using Prognoscan database.
• In vivo metastasis model using intravenous injection of ADAM9-downregulated A549 cells in nude mice.
• Subcutaneous xenograft model to assess tumor growth and angiogenesis.
• In vitro angiogenesis assays with human umbilical vein endothelial cells.
• Human antibody array analysis to identify differentially expressed cytokines.

Main Results:

• High ADAM9 expression in lung adenocarcinoma patients correlates with poor prognosis.
• Downregulation of ADAM9 significantly reduced lung metastasis and tumor growth in vivo.
• ADAM9-deficient cells exhibited reduced angiogenesis, evidenced by fewer neovessels in tumors and impaired endothelial cell network formation in vitro.
• Interleukin 8 was identified as a key downregulated cytokine in ADAM9-deficient cells, implicating its interaction with CXCR2 in angiogenesis.

Conclusions:

• ADAM9 plays a critical role in promoting lung cancer progression, metastasis, and angiogenesis.
• ADAM9 serves as a potential biomarker for cancer aggressiveness.
• Targeting ADAM9 presents a promising therapeutic strategy for lung cancer treatment.